• Explore /
  • Poster
  • / A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.

A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.

Abstract Poster

Authors

null

Esther Pijnappel

Amsterdam UMC Location AMC, Amsterdam, Netherlands

Esther Pijnappel , Judith de Vos-Geelen , Teresa Macarulla Mercade , Davide Melisi , Per Pfeiffer , Gerald W. Prager , Hanneke W.M. Van Laarhoven , Johanna Wilmink

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03986294

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4664)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4664

Abstract #

TPS4664

Poster Bd #

272

Abstract Disclosures

Similar Posters

First Author: Benedikt Westphalen

First Author: Thomas Jens Ettrich

First Author: Thomas Jens Ettrich

First Author: Yu Jo Chua